PharmaBiome specializes in the isolation and characterization of intestinal microbes to engineer function-based bacterial consortia that restore metabolic balance in the gut. Their technology addresses dysbiosis by tailoring microbial therapies to specific diseases, enhancing therapeutic efficacy through a deep understanding of microbiome interactions.
Funding
$6.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Dysbiosis, or imbalance in the gut microbiome, can disrupt essential metabolic functions and contribute to various diseases. Current microbiome therapies often lack specificity and fail to address the complex interactions within the microbial ecosystem. This can limit their effectiveness in restoring gut health and treating related conditions.
Solution
PharmaBiome engineers function-based bacterial consortia to restore metabolic balance in the gut and treat diseases linked to microbiome dysbiosis. They isolate and characterize intestinal microbes, then design tailored microbial therapies based on a deep understanding of microbiome function and interactions. Their approach focuses on engineering bacterial consortia based on their metabolic interactions, selecting individual strains to assemble and co-culture using their technology. By targeting specific functionalities rather than just individual strains, PharmaBiome aims to create versatile and balanced consortia that can effectively reverse dysbiosis and improve patient outcomes.
Target Audience
PharmaBiome's primary target audience includes pharmaceutical companies and researchers focused on developing microbiome-based therapies for various diseases.
Features
- Function-based approach to microbiome engineering, focusing on restoring metabolic balance.
- Isolation and characterization of a wide range of intestinal bacteria.
- Design of tailored microbial therapies specific to different diseases.
- Co-cultivation technology for assembling and optimizing bacterial consortia.
- Focus on the science of the microbiome as a network.